PDGFR in myelodysplastic/myeloproliferative neoplasms

1 EU-approved indication in myelodysplastic/myeloproliferative neoplasms needs a PDGFR result: imatinib (any line).

Line of therapy

Approved indications, Myelodysplastic/myeloproliferative neoplasms
DrugBiomarker requirementRegimenSettingConditions
PDGFR fusion1
Imatinib
Glivec
Monotherapy
Any line
None

See also

Label wording1

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Imatinib (Glivec)
    adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.